Healthcare Industry Outlook For Trump Admin
- Healthcare stocks performed well during Trump's first term, despite increased uninsured rates and reduced regulation, with insurance companies outperforming biotech and pharma sectors.
- Reduced federal research funding and high interest rates negatively impacted biotech and pharma, causing underperformance and highlighting potential future risks in these sectors.
- A favorable business environment under Trump, particularly for M&A, could benefit struggling biotechs, though regulatory and quality control risks remain significant.
- Diversification is key; consider broad healthcare ETFs like XLV, private insurers via IHF, and equipment makers via XHE to mitigate individual company risks.
filo/E+ via Getty Images
The major factors influencing the healthcare industry during Trump's first term were based on both the rebound from the post-recession biotech surge and ACA spending. Due to the fact that the healthcare industry moves slower due to
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
